We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Genetic Cause Identified for Neurodevelopmental Disorder

By LabMedica International staff writers
Posted on 05 Aug 2026

For many families, the reason a child fails to meet developmental milestones can remain unclear for years. More...

These neurodevelopmental conditions often involve developmental delay, autism, and, in some cases, epilepsy, complicating efforts to pinpoint an underlying cause. Investigators have now identified a genetic explanation for a subset of previously unexplained cases. New findings demonstrate how alterations in a single gene disrupt neuronal signaling and align with a recurring clinical presentation.

At the Leibniz Institute for Neurobiology (LIN; Magdeburg, Germany), an international team linked de novo variants in the NPTN gene to a rare neurodevelopmental disorder marked by developmental delay or intellectual disability and frequent autism diagnoses. NPTN encodes the protein neuroplastin, and the study provides evidence that changes in this gene can contribute to neurodevelopmental disorders and autism. The work was published in Genome Medicine on July 1, 2026.

The researchers detailed how NPTN alterations impair neuroplastin’s role in regulating neuronal calcium balance. Altered neuroplastin was shown to perform this function unreliably, leading to less effective activity of certain calcium pumps known as PMCA pumps that normally remove excess calcium from cells. Prolonged calcium activity can disrupt signal processing in nerve cells and impair the development of neural networks.

The study examined eight children for whom no clear cause of a developmental disorder had previously been identified and found NPTN changes in all eight. All experienced developmental delays or intellectual disabilities; seven had been diagnosed with autism. Some also developed epilepsy, lost previously acquired language skills, or showed abnormalities in movement and sleep. In every case, the genetic changes had arisen spontaneously rather than being inherited from the parents.

To probe the mechanism, the team combined genetic analyses with experiments in cell cultures and animal models. They observed markedly altered calcium signals in nerve cells. In mice, reducing neuroplastin by half led to a substantial decline in key calcium pumps in the brain, in some cases by almost 50%, and animals displayed reduced interest in social interaction. Experiments in fruit flies provided additional evidence that changes in neuroplastin impair protein function.

According to the authors, the results provide a foundation for identifying similar cases and can help affected families move toward a definitive diagnosis and a clearer assessment of likely disease course. The team is investigating whether the disrupted calcium signaling pathways can be influenced and when an intervention might be effective. Further research is needed because only eight affected children have been identified to date.

“Our findings show that neuroplastin plays an important role in the brain. If the protein is altered or if the body does not produce enough of it, nerve cells may no longer be able to process signals correctly,” said PD Dr. Dirk Montag of the Leibniz Institute for Neurobiology.

“The strength of this study lies in establishing a direct link between the clinical observations and the underlying molecular mechanisms,” added Montag.

Related Links
Leibniz Institute for Neurobiology


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.